Treatment response rate and life prognosis at autoimmune liver diseases

Abstract

The aim of review. To carry out comparative analysis of modern studies, to characterize actual modes of treatment and to define prognosis and features of treatment response at various autoimmune liver diseases.Key points. Diagnostics and treatment are the most complex and insufficiently investigated aspects of autoimmune liver diseases. Due to large studies, clinicians gain some understanding of approaches to therapy of these patients. Article presents up-to-date management algorithms and new promising agents, demonstrates complexities and alternative variants of treatment of autoimmune liver diseases.Conclusion. Appropriate and long-term (for 12–24 months) therapy of autoimmune diseases in most cases allows to achieve sustained response and in several folds surpasses efficacy of short courses (6–12 months).

Keywords

• autoimmune hepatitis
• primary biliary cirrhosis
• primary sclerosing cholangitis
• overlap syndromes